Global Information
회사소개 | 문의 | 비교리스트

겸상 적혈구병 : 파이프라인 리뷰

Sickle Cell Disease - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 213124
페이지 정보 영문 271 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


겸상 적혈구병 : 파이프라인 리뷰 Sickle Cell Disease - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 271 Pages

겸상 적혈구병(겸상 적혈구 빈혈)이란 유전성(선천성) 혈액 질환으로, 혈액내 적혈구가 이상 형상이 되는 것입니다. 주요 징후·증상에는 빈혈 및 발달 지연, 시야 장애, 통증, 감염증에 대한 빈번한 감염 등을 들 수 있습니다. 주요 치료법에는 항생제 및 진통제, 수혈, 줄기세포 이식 등이 있습니다.

세계 각국에서의 겸상 적혈구병 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

겸상 적혈구병의 개요

치료제 개발

  • 파이프라인 제품 개요
  • 파이프라인 제품 비교 분석

겸상 적혈구병 : 기업에서 개발중인 치료제

겸상 적혈구병 : 대학/기관에서 연구중인 치료제

겸상 적혈구병 : 파이프라인 제품의 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계 불명의 제품

겸상 적혈구병 : 기업에서 개발중인 제품

겸상 적혈구병 : 대학/기관에서 연구중인 제품

겸상 적혈구병 치료제 개발에 참여하고 있는 기업

  • Acceleron Pharma, Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • Advinus Therapeutics Ltd.
  • Alnylam Pharmaceuticals, Inc.
  • BioAegis Therapeutics, Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Complexa, Inc.
  • CSL Limited
  • Dilaforette AB
  • Editas Medicine, Inc.
  • Emmaus Medical, Inc.
  • Errant Gene Therapeutics, LLC
  • Gamida Cell Ltd.
  • Gilead Sciences, Inc.
  • Global Blood Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • La Jolla Pharmaceutical Company
  • Merck & Co., Inc.
  • Morphogenesis, Inc.
  • NKT Therapeutics, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.
  • PharmaEssentia Corporation
  • Prolong Pharmaceuticals, LLC
  • ReveraGen BioPharma, Inc.
  • Sancilio & Company, Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

겸상 적혈구병 : 치료제 평가

  • 단일요법 제품
  • 병용 제품
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

약제 개요

겸상 적혈구병 : 최근 파이프라인 동향

겸상 적혈구병 : 휴지중인 프로젝트

겸상 적혈구병 : 개발이 중지된 제품

겸상 적혈구병 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 16.06.10

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Sickle Cell Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Sickle Cell Disease - Pipeline by Agios Pharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Alkermes Plc, H1 2020
  • Sickle Cell Disease - Pipeline by Angiocrine Bioscience Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Annexin Pharmaceuticals AB, H1 2020
  • Sickle Cell Disease - Pipeline by Aruvant Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Axcella Health Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Beam Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by bluebird bio Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Sickle Cell Disease - Pipeline by C4X Discovery Holdings Plc, H1 2020
  • Sickle Cell Disease - Pipeline by Cannabis Science Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Cell Source Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Cetya Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by CRISPR Therapeutics AG, H1 2020
  • Sickle Cell Disease - Pipeline by CSL Ltd, H1 2020
  • Sickle Cell Disease - Pipeline by Cyclerion Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Dystrogen Therapeutics SA, H1 2020
  • Sickle Cell Disease - Pipeline by Editas Medicine Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Emmaus Life Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Epidestiny Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Epizyme Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Errant Gene Therapeutics LLC, H1 2020
  • Sickle Cell Disease - Pipeline by ExCellThera Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Forma Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Fulcrum Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Functional Fluidics LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Gamida Cell Ltd, H1 2020
  • Sickle Cell Disease - Pipeline by Gilead Sciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Global Blood Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Glycan Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Hillhurst Biopharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Homology Medicines Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Imara Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Intellia Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Invenux LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Medeor Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Merck & Co Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Micelle BioPharma Inc, H1 2020
  • Sickle Cell Disease - Pipeline by MimeTech Srl, H1 2020
  • Sickle Cell Disease - Pipeline by Modus Therapeutics AB, H1 2020
  • Sickle Cell Disease - Pipeline by Molecules For Health Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Novartis AG, H1 2020
  • Sickle Cell Disease - Pipeline by Oryzon Genomics SA, H1 2020
  • Sickle Cell Disease - Pipeline by PHD Biosciences, H1 2020
  • Sickle Cell Disease - Pipeline by Phoenicia Biosciences Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Rare Partners Srl, H1 2020
  • Sickle Cell Disease - Pipeline by Regenacy Pharmaceuticals LLC, H1 2020
  • Sickle Cell Disease - Pipeline by ReNeuroGen LLC, H1 2020
  • Sickle Cell Disease - Pipeline by Sangamo Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Secura Bio Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Syros Pharmaceuticals Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Tarus Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Trucode Gene Repair Inc, H1 2020
  • Sickle Cell Disease - Pipeline by Vanguard Therapeutics Inc, H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Sickle Cell Disease - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Sickle Cell Disease - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Sickle Cell Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Sickle Cell Disease (Hematological Disorders) pipeline landscape.

Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Sickle Cell Disease (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sickle Cell Disease (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 11, 4, 26 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 1 molecules, respectively.

Sickle Cell Disease (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Sickle Cell Disease (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Sickle Cell Disease (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Sickle Cell Disease (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Sickle Cell Disease (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Sickle Cell Disease (Hematological Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Sickle Cell Disease (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Sickle Cell Disease (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Sickle Cell Disease - Overview
  • Sickle Cell Disease - Therapeutics Development
  • Sickle Cell Disease - Therapeutics Assessment
  • Sickle Cell Disease - Companies Involved in Therapeutics Development
  • Sickle Cell Disease - Drug Profiles
  • Sickle Cell Disease - Dormant Projects
  • Sickle Cell Disease - Discontinued Products
  • Sickle Cell Disease - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q